Not to be used for acute asthma symptoms. Prophylactic use in exercise-induced asthma. Not to be initiated during exacerbation, or if patient has significantly worsening or acutely deteriorating asthma. Serious asthma-related AR & exacerbations. Not to be used as 1st treatment for asthma. Potentially life-threatening sudden & progressive deterioration in asthma control. Not to be stopped abruptly in patients w/ asthma due to risk of exacerbation. Patients w/ pulmonary or quiescent TB, fungal, viral or other airway infections; w/ thyrotoxicosis, phaeochromocytoma, DM, uncorrected hypokalaemia or predisposed to low levels of serum K, hypertrophic obstructive cardiomyopathy, idiopathic subvalvular aortic stenosis, severe HTN, aneurysm or other severe CV disorders eg, ischaemic heart disease, cardiac arrhythmias or severe heart failure. Potentially serious hypokalaemia. Monitor serum K levels in patients w/ unstable or acute severe asthma & in other conditions w/ increased likelihood for hypokalaemia AR. Patients w/ existing QTc interval prolongation. Additional blood sugar control in diabetics. Impaired adrenal function from previous systemic steroid therapy. Discontinue immediately if paradoxical bronchospasm occurs w/ an immediate increase in wheezing & shortness of breath after dosing. Visual disturbance. Potential systemic effects on prolonged high-dose treatment including adrenal suppression & acute adrenal crisis, Cushing's syndrome, Cushingoid features, growth retardation in childn & adolescents, decreased bone mineral density, cataract, glaucoma & more rarely, psychomotor hyperactivity, sleep disorders, anxiety, depression or aggression (particularly in childn). Regularly monitor hypothalamic pituitary adrenocortical axis function. Not to be used w/ an additional long-acting β2
-agonists. Concomitant use w/ potent CYP3A4 inhibitors. Severe hepatic impairment. Not recommended during pregnancy. Lactation. Not recommended for childn <5 yr.